Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream.

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

As GLP-1 RA use soars, experts are worried that patients may not be getting the right nutrients in their diets. How can ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

To attract and retain workers, employers will focus on competitive salaries and flexible benefits, experts say.

This is the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Last year, Thrive Global teamed up with OpenAI to create Thrive AI Health, an AI-powered health coach trained on the ...

From GLP-1s to brand product innovation, the trend intelligence report details the overall surge of innovation and investment in women’s health technologies at the 2025 CES on Monday.

Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

Beyond the influence of new therapies on drug pricing trends, Cowen’s report also accounted for the effects of legislation ...